Results 1 to 10 of about 70 (39)
Human Vaccines & Immunotherapeutics, 2017 Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA).
Martin Sheppard +4 more
openaire +3 more sources
mAbs, 2009 Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is ...
openaire +2 more sources
Some of the next articles are maybe not open access.
Tocilizumab in transplantation
European Journal of Clinical Pharmacology, 2020Tocilizumab, a monoclonal antibody directed against the IL-6 receptor, might block detrimental effects of IL-6 on transplantation. IL-6 plays a considerable role in cytokine storm after stem cell transplantation as well as graft versus host disease, and it has also been shown to be involved in solid organ allograft rejection; therefore, tocilizumab is ...
Banafsheh, Mosharmovahed +4 more
openaire +2 more sources
CT-P47/Tocilizumab-anoh: A Tocilizumab Biosimilar
Clinical Drug InvestigationCT-P47/tocilizumab-anoh (AVTOZMA®) is a biosimilar of reference tocilizumab, an IL-6R inhibitor. CT-P47 is approved for treating rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, Coronavirus disease 2019 and cytokine release syndrome in the USA and the EU. CT-P47 has similar
openaire +2 more sources